News
06 July 2020

EIB agrees €75m financing for Germany's CureVac

In:
Social infrastructure
Region:
Europe

The European Investment Bank has signed a €75 million loan agreement with Germany-based CureVac, a clinical-stage biopharmaceutical company.

The financing will support the company’s ongoing development of vaccines against infectious diseases, including its vaccine candidate CVnCoV aimed at preventing SARS-CoV-2 infections. 

In addition, the loan will support CureVac's efforts to expand its existing Good Manufacturing Practice certified production capabilities and accelerate the completion of its fourth production site in Tubingen, Germany. The EIB financing will be provided in three €25 million tranches upon completion of pre-defined milestones.

You might also like


Interview
07 May 2024

Shona Tatchell: EBRD's new head of trade facilitation on...

In her first interview since her appointment on 7 May, Shona Tatchell, the new head of trade and supply chain finance, European Bank for Reconstruction & Development (EBRD)...

Perspective
17 May 2024

Financing last-mile connections in Africa

Low-income household energy projects in Africa are increasingly being financed via securitisation structures. The deals are relatively small, but the impact could prove as...